npj Breast Cancer · 2022 · 16 citations · 37 references
MedicineOncologyPharmacologyAgingChemotherapyMolecular OncologyCancer BiomarkersGeriatric OncologyNeuropathology Of AgingPeripheral Neuropathy EvaluationToxicity GradingAge-specific Risk AssessmentCellular Senescence MarkersChronological Age EffectsP16 ExpressionPeripheral Neuropathy PathophysiologyPeripheral Neuropathy RiskTaxane ChemotherapyTaxane-based Chemotherapy
Identifying patients at higher risk of chemotherapy-induced peripheral neuropathy (CIPN) is a major unmet need given its high incidence, persistence, and detrimental effect on quality of life. We determined if the expression of p16, a biomarker of aging and cellular senescence, predicts CIPN in a prospective, multi-center study of 152 participants enrolled between 2014 and 2018. Any women with newly diagnosed Stage I-III breast cancer scheduled to receive taxane-containing chemotherapy was eligible. The primary outcome was development of grade 2 or higher CIPN during chemotherapy graded by the clinician before each chemotherapy cycle (NCI-CTCAE v5 criteria). We measured p16 expression in peripheral blood T cells by qPCR before and at the end of chemotherapy. A multivariate model identified risk factors for CIPN and included taxane regimen type, p16Age Gap, a measure of discordance between chronological age and p16 expression, and p16 expression before chemotherapy. Participants with higher p16Age Gap-higher chronological age but lower p16 expression prior to chemotherapy - were at the highest risk. In addition, higher levels of p16 before treatment, regardless of patient age, conferred an increased risk of CIPN. Incidence of CIPN positively correlated with chemotherapy-induced increase in p16 expression, with the largest increase seen in participants with the lowest p16 expression before treatment. We have shown that p16 expression levels before treatment can identify patients at high risk for taxane-induced CIPN. If confirmed, p16 might help guide chemotherapy selection in early breast cancer.
37
Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
Darren J. Baker, Tobias Wijshake, Tamar Tchkonia et al. · Nature · 2011 · 3.6K citations · Full text
Naturally occurring p16Ink4a-positive cells shorten healthy lifespan
Darren J. Baker, Bennett G. Childs, Matej Durik et al. · Nature · 2016 · 2.8K citations · Full text
Senolytics improve physical function and increase lifespan in old age
Ming Xu, Tamar Pirtskhalava, Joshua N. Farr et al. · Nature Medicine · 2018 · 2.2K citations
Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline
Tyler J. Bussian, Asef Aziz, Charlton F. Meyer et al. · Nature · 2018 · 1.3K citations
Senescent intimal foam cells are deleterious at all stages of atherosclerosis
Bennett G. Childs, Darren J. Baker, Tobias Wijshake et al. · Science · 2016 · 1.1K citations · Full text